Free Daily Podcast Summary
Touching Base: Daily Summaries Delivered
by Genetic Engineering & Biotechnology News (GEN)
Touching Base is the dynamic podcast series from the editors of GEN (Genetic Engineering & Biotechnology News). Each episode features a rotating cast of senior editors including John Sterling, Kevin Davies, Julianna LeMieux, Alex Philippidis, Uduak Thomas, Corinna Singleman and Fay Lin who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Aug 13, 202637 min
BMS’s New Facility, Recursion–Genentech Partnership, Long-COVID and Persistent C.auris
Bristol Myers Squibb has selected Houston as the site for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufacturing from late development through launch. Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on the first validated target discovered through an AI map. Editors reminisce over the changes in science since the COVID-19 pandemic in light of a new large NIH-funded study that shows COVID-19 can reactivate dormant viruses, including Epstein-Barr and cytomegalovirus. In other infectious disease news, drug-resistant Candida auris was found to persist in hair follicles by exposing chitin, triggering interferon-γ that suppresses skin defenses and creates a niche for fungal colonization.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Julianna LeMieux, PhD, for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: BMS Chooses Houston for $2.3B Manufacturing FacilityBy Alex Philippidis, GEN Edge, Aug 10, 2026Next 10 U.S. Biopharma ClustersBy Alex Philippidis, GEN, Aug 12, 2026Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI MapBy Alex Philippidis, GEN Edge, Aug 5, 2026COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVIDGEN, Aug 5, 2026Trump’s Treatments: Regeneron’s Antibodies and Gilead’s Remdesivir ExplainedBy Alex Philippidis, GEN, Oct 5, 2020Lessons from the COVID Crisis: An Interview with Peter HotezBy Alex Philippidis, GEN Edge, Oct 19, 2022How to Conquer Coronavirus: Top 35 Treatments in DevelopmentBy Alex Philippidis, GEN, March 2, 2020Candida auris Persists in Hair Follicles, Hijacks Immune SignalingGEN, August 10, 2026The State of Biotech SummitSeptember 23, 2026 Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD The State of Biologics Testing 2026Charles River Laboratories and GEN, June 10, 2026Subscribe to GEN’s newsletters Hosted on Acast. See acast.com/privacy for more information.
- Jul 31, 202632 min
Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s
In the business news section of this week’s episode, Axiom Biosciences recently announced its plans to go public and made headlines for its plans to do so on the Hong Kong Exchange rather than a U.S. market. We dig into the company’s reasoning. Then we turn our attention to Latigo’s report of positive Phase IIb data for its non-opioid acute pain candidate, and its plans to go through a planned IPO soon. Switching to some science news, we discuss findings from a study that identified genetic risk factors for fibromyalgia syndrome as well as links to other neurodegenerative, autoimmune, and metabolic diseases. And lastly, a potential base editing therapy for Huntington’s disease that has shown promise in mice.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: StockWatch: Axiom CEO Explains Plans for Hong Kong IPO By Alex Philippidis, GEN Edge, July 27, 2026Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate By Alex Philippidis, GEN Edge, July 30, 2026Genetic Study of Fibromyalgia Points to Neurological Basis GEN, July 29, 2026Base Editing Strategy Alleviates Huntington’s Disease in Mice GEN, July 29, 2026Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD The State of Biologics Testing 2026Charles River Laboratories and GEN, June 10, 2026 Hosted on Acast. See acast.com/privacy for more information.
- Jul 17, 202632 min
Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics
Promise hits Parkinson’s disease therapy, as a Phase I/II clinical study has demonstrated the feasibility of transplanting stem-cell-derived dopamine progenitor cells into the brain. In preclinical research, a new platform uses the brain’s fluid transport pathways to effectively deliver AAVs to therapeutic targets in mice. We’ll also cover the accelerating infrastructure moment for AI-driven drug discovery, with billion-dollar investments flowing into end-to-end platforms driven by models and compute, rather than single drug assets. In business, Insilico’s revenue leaps as the company’s AI-developed lead candidate moves to Phase III, while Vertex acquires Crinetics for $10 billion. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: Engineered AAVs Harness Glymphatic System to Reach Brain Targets in Mice GEN, July 9, 2026 Stem Cell Therapy Shows Promise in First Human Parkinson’s Disease Trial GEN, July 9, 2026 Pharma Races to Scale AI as Billions Flow into Drug Discovery By Fay Lin, PhD, GEN Edge, July 6, 2026 StockWatch: Insilico Projects Profit, Revenue Leaps as AI-Developed Lead Candidate Moves to Phase III By Alex Philippidis, GEN Edge, July 12, 2026 Vertex Eyes Expansion Beyond Cystic Fibrosis with Planned $10B Crinetics Buyout By Alex Philippidis, GEN Edge, July 7, 2026 Top 20 Drugs Heading for the Patent Cliff, 2026-2029 By Alex Philippidis, GEN Magazine, Nov 1, 2025 Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD The State of Biologics Testing 2026 Charles River Laboratories and GEN, June 10, 2026 Hosted on Acast. See acast.com/privacy for more information.
- Jul 2, 202635 min
Merck and Insilico Make Deals, Claude Science’s Debut, Vaccines for Neglected Diseases
More big biotech deals on the docket this week. First, Merck KGaA is buying Bio-Techne for $11.3 billion to expand its presence in high-growth life science markets. We dive into the details of this deal and then turn our attention to a $2.5 million collaboration to use artificial intelligence to find drug candidates for neuroimmune disorders. That deal involves Insilico Medicine and SK Biopharmaceuticals. Still on the theme of AI, we discuss Anthropic’s Claude Science, the latest entrant to the growing ecosystem of tech platforms specialized for biology, and a set of models for antibiotic design and vaccine target prediction. Lastly, we dig into two recent publications that discuss vaccines for Nipah virus and one of its relatives, and for treating schistosomiasis.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: Merck KGaA to Acquire Bio-Techne for $11.3B, Expanding Life Science Tools Presence By Alex Philippidis, GEN Edge, June 25, 2026Insilico, SK Launch Up-to-$2.5B Neuroimmune AI Drug CollaborationBy Alex Philippidis, GEN Edge, June 28, 2026Claude Science Is Here, Antibiotics Designed by Text Prompt Among Applications By Fay Lin, PhD, GEN Edge, June 30, 2026Schistosomiasis Vaccine Shows Strong Immune Memory in Early Clinical TrialsGEN, June 29, 2026 Nipah and Hendra Viruses: Antibody Cocktail Provides Complete Protection in Hamster ModelGEN, June 26, 2026Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD Hosted on Acast. See acast.com/privacy for more information.
- Jun 18, 202634 min
Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccine
We are still talking about big pharma deals and biotech fundraising in this episode. The big news this week was Parabilis Medicines’s history-making IPO. We dive into the drug developer’s plans for the eye-popping $770.5 million that it raised. Next, we discuss the details of a collaboration between Merck and Protillion Biosciences to use artificial intelligence to discover multiple therapeutic candidates. Turning to some newly published research, we discuss the early results of a first-in-human clinical trial that is testing a dual vaccine against Lassa fever and rabies, a CRISPR system engineered to selectively trigger cancer cell death by chromatin shredding, and a novel mRNA delivery platform for delivering gene therapies starting with Duchenne muscular dystrophy. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Uduak Thomas, and Fay Lin, PhD, for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPOBy Alex Philippidis, GEN Edge, June 14, 2026Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone PaymentsBy Alex Philippidis, GEN Edge, June 16, 2026First-in-Human Trial Reports Promising Dual Lassa–Rabies Vaccine DataGEN, June 9, 2026CRISPR Shreds Undruggable Cancer Cells with PrecisionBy Fay Lin, PhD, GEN Edge, June 8, 2026New mRNA Delivery Platform Restores Muscle Function in DMD ModelsGEN, June 11, 2026Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD Hosted on Acast. See acast.com/privacy for more information.
- Jun 4, 202637 min
A Billion-Dollar Deal, Trial Trouble, Biohub Updates, and Vaccine Research News
In this week’s episode, we start with news that Fulcrum Therapeutics is scrapping its lead pipeline program for sickle cell disease following concerns from the FDA about the drug’s risks and benefits. Also on the docket, news of Eli Lilly’s latest spending. The pharma giant has added its genetic medicines pipeline and capabilities by signing a $1.9 billion agreement with Ascidian Therapeutics to develop RNA exon editors for treating inherited kidney diseases. Next up, updates to an open-source model for binder design and protein function mapping. Finally, on the peer-review front, we dive into some of the latest vaccine research including insights into the mechanisms that cross-reactive T cells use to target multiple viral species in a single family and an improvement to standard polio vaccines. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: Fulcrum Halts Development of SCD Candidate Pociredir, Sets Strategic ReviewBy Alex Philippidis and Kevin Davies, PhD, GEN Edge, June 2, 2026 Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney DiseasesBy Alex Philippidis, GEN Edge, June 3, 2026 Biohub Releases Protein Biology World Model to Address DiseaseBy Fay Lin, PhD, GEN Edge, May 27, 2026 Cross-Reactive T Cells Could Point to Broad Vaccines or Treatments for Measles, Nipah VirusGEN, June 2, 2026Experimental Adjuvant Could Strengthen Mucosal Immunity with Injectable Polio Vaccines GEN, June 4, 2026Touching Base Podcast Hosted by Corinna Singleman, PhD Hosted on Acast. See acast.com/privacy for more information.
- May 22, 202632 min
AI Scientists, Stock Tumble, Patent Lawsuit, and New Partnerships
Agentic AI is growing in its applications. Google Deep Mind and Edison are leveraging the growing capabilities by developing AI Scientists. These platforms are poised to streamline the scientific process, aiding human scientists with a variety of tasks. Meanwhile, despite positive data in its Phase III DMD therapy trial, Regenxbio’s stock fell for a variety of reasons. 10X Genomics and Harvard University are suing Element Biosciences over patents for a multiomics platform. Finally, Bristol Meyers Squibb is partnering with Hengrui Pharma to develop 13 early-stage programs with the potential to grow their investment to a predicted $15 billion in sales. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: Google DeepMind and Edison Are Building the AI Scientist By Fay Lin, PhD, GEN Edge, May 19, 2026StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy CandidateBy Alex Philippidis, GEN Edge, May 17, 2026 10x Genomics, Harvard Target Element’s Multiomics Platform in Patent Lawsuit By Alex Philippidis, GEN Edge, May 12, 2026 BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration By Alex Philippidis, GEN Edge, May 13, 2026Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD The State of Precision Medicine SummitJoin us June 3, 2026 Hosted on Acast. See acast.com/privacy for more information.
- May 7, 202643 min
Remembering J. Craig Venter, PhD
Craig Venter recently passed away at the age of 79 from complications following a cancer diagnosis. He was well known in both science and industry and was an integral part of sequencing the human genome in the late 90s, competing with the government organized Human Genome Project. Through his career, he made many other important contributions in microbiology, with the “minimal cell”, in synthetic biology, and in personalized medicine. GEN editors share anecdotes of their experiences with him, reflect on the impact that his work has had on various fields in biology, in biotech, and in how the world has responded to the disruptions caused by Venter. Join GEN editors Corinna Singleman, PhD, John Sterling, Kevin Davies, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: Genomics Pioneer and Life Sciences Entrepreneur J. Craig Venter Dies at 79 GEN, April 30, 2026 J. Craig Venter Describes a Human Genomics Revolution Still In ProgressBy J. Craig Venter, PhD, GEN, June 13, 2025 Lessons from the Minimal CellBy Hana El-Samad, PhD, GEN, August 21, 2023 From Sequencing to Sailing: Three Decades of Adventure with Craig VenterBy Fay Lin, PhD, GEN, March 8, 2023 “Cracking the Genome” By Kevin Davies, PhDTouching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD Hosted on Acast. See acast.com/privacy for more information.
Get Touching Base summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Nature Podcast
Covers breakthrough research from Nature journal across all scientific fields, with insights from scientists and science journalists.
TechSurge: Deep Tech Podcast
Explores emerging technologies, startup challenges, and investment trends through interviews with tech leaders, founders, and investors.
Latent Space: The AI Engineer Podcast
Explores AI engineering breakthroughs in foundation models, code generation, and AI agents through interviews with researchers and developers.
Solutions with Henry Blodget
Henry Blodget interviews experts in business, tech, and politics about practical solutions for building a better future.
Science Magazine Podcast
Weekly episodes covering original scientific research, global science news, and expert commentary.
Brave New Planet
Explores the societal and ethical impacts of emerging technologies like AI and genetic engineering through expert conversations.
Primary Technology
Tech news covering consumer gadgets, AI, and major industry stories explained for a general audience.
Everyday AI Podcast – An AI and ChatGPT Podcast
Practical AI and ChatGPT tips for professionals to improve productivity and grow their careers.
All-In with Chamath, Jason, Sacks & Friedberg
Four tech investors discuss technology, markets, politics, and poker with candid, in-depth analysis.
Genetics Unzipped
Explores stories from the world of genetics, from Mendel's experiments to modern genome research.
Moonshots with Peter Diamandis
Explores emerging technologies and their potential to transform humanity's future.
Babbage from The Economist
A weekly exploration of science and technology, from AI and genetics to space travel, featuring interviews with leading researchers.
About Touching Base
Touching Base is the dynamic podcast series from the editors of GEN (Genetic Engineering & Biotechnology News). Each episode features a rotating cast of senior editors including John Sterling, Kevin Davies, Julianna LeMieux, Alex Philippidis, Uduak Thomas, Corinna Singleman and Fay Lin who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Touching Base in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Touching Base daily summary?
It's a free AI-powered email that summarizes new episodes of Touching Base as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Touching Base podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Touching Base product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Genetic Engineering & Biotechnology News (GEN).
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does Touching Base release new episodes?
Touching Base publishes biweekly. Our AI generates a summary within hours of each new episode.
What topics does Touching Base cover?
Touching Base covers topics including Science, News, Commentary, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Touching Base summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.